Abstract
Adenocarcinoma of the pancreas is the fourth leading cause of cancer-related death in the United States. Therapeutic responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy is poor, resulting in a dismal 5-year survival of less than 3%. Point mutation of the K-ras oncogene is a common event in the early development of pancreatic cancer. Indeed, K-ras mutations occur in up to 95% of pancreatic cancers, with a resulting overall increase in production of reactive oxygen species (ROS) through the activation of NADPH oxidase (NOX). Specifically, the extracellular (non-mitochondrial) generation of superoxide (O2.-) from the NOX system results in cell growth and tumor progression. Extracellular superoxide dismutase (SOD3, EcSOD) is the only isoform of superoxide dismutase (SOD) expressed extracellularly. It modulates ROS by converting O2.- into hydrogen peroxide (H2O2). Antioxidant enzymes that scavenge specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. It has been demonstrated that overexpression of EcSOD inhibits pancreatic cancer cell growth and intracellular signaling pathways. Therefore, we propose that strategies to scavenge non-mitochondrial-generated superoxide may prove beneficial in the treatment pancreatic cancer. This review will focus on the role of O2.- as a pro-tumorigenic signaling molecule, including its generation and hypothesized mechanism of action, as well as the role of EcSOD in inhibiting tumor growth and propagation, and its potential as a targeted pancreatic cancer therapy.
Keywords: Superoxide, pancreatic cancer, superoxide dismutase, hypoxia-inducible factor-1α.
Current Cancer Therapy Reviews
Title:Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Volume: 9 Issue: 4
Author(s): John A. Cieslak and Joseph J. Cullen
Affiliation:
Keywords: Superoxide, pancreatic cancer, superoxide dismutase, hypoxia-inducible factor-1α.
Abstract: Adenocarcinoma of the pancreas is the fourth leading cause of cancer-related death in the United States. Therapeutic responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy is poor, resulting in a dismal 5-year survival of less than 3%. Point mutation of the K-ras oncogene is a common event in the early development of pancreatic cancer. Indeed, K-ras mutations occur in up to 95% of pancreatic cancers, with a resulting overall increase in production of reactive oxygen species (ROS) through the activation of NADPH oxidase (NOX). Specifically, the extracellular (non-mitochondrial) generation of superoxide (O2.-) from the NOX system results in cell growth and tumor progression. Extracellular superoxide dismutase (SOD3, EcSOD) is the only isoform of superoxide dismutase (SOD) expressed extracellularly. It modulates ROS by converting O2.- into hydrogen peroxide (H2O2). Antioxidant enzymes that scavenge specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. It has been demonstrated that overexpression of EcSOD inhibits pancreatic cancer cell growth and intracellular signaling pathways. Therefore, we propose that strategies to scavenge non-mitochondrial-generated superoxide may prove beneficial in the treatment pancreatic cancer. This review will focus on the role of O2.- as a pro-tumorigenic signaling molecule, including its generation and hypothesized mechanism of action, as well as the role of EcSOD in inhibiting tumor growth and propagation, and its potential as a targeted pancreatic cancer therapy.
Export Options
About this article
Cite this article as:
A. Cieslak John and J. Cullen Joseph, Extracellular Superoxide and the Growth of Pancreatic Carcinoma, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418095056
DOI https://dx.doi.org/10.2174/157339470904140418095056 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Comparative Proteomic Analysis Reveals Novel Biomarkers for Gastric Cancer in South Indian Tamil Population
Combinatorial Chemistry & High Throughput Screening In vitro Evaluation of Helicobacter pylori Inhibition by Artemisia absinthium and Eugenia caryophyllata Extracts with Black Seeds Honey
The Natural Products Journal Long-Term Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer/Esophagogastric Junction Cancer: A Systematic Review and Meta-Analysis
Anti-Cancer Agents in Medicinal Chemistry An Overview of the Chemistry and Pharmacological Potentials of Furanones Skeletons
Current Organic Chemistry QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Recent Development in the Field of Dual COX / 5-LOX Inhibitors
Mini-Reviews in Medicinal Chemistry Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Editorial: Role of Cancer Stem Cells in Common Gastrointestinal Cancers: From Pathogenesis to Therapeutic Targets
Current Stem Cell Research & Therapy Immunosensors in Early Cancer Diagnostics: From Individual to Multiple Biomarker Assays
Current Medicinal Chemistry Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Clinical Proteomics in Cancer Research – Promises and Limitations of Current Two-Dimensional Gel Electrophoresis
Current Medicinal Chemistry Pharmaceutical Approaches for Optimizing Oral Anti-Inflammatory Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Non-Invasive Imaging of Complicated Osteomyelitis: The Added Value of Scintigraphic Techniques
Current Radiopharmaceuticals